OR4C13 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sodium azide | 26628-22-8 | sc-208393 sc-208393B sc-208393C sc-208393D sc-208393A | 25 g 250 g 1 kg 2.5 kg 100 g | $42.00 $152.00 $385.00 $845.00 $88.00 | 8 | |
Sodium azide disrupts ATP production by inhibiting mitochondrial cytochrome c oxidase. Since ATP is vital for the energy-dependent conformation of OR4C13, its inhibition can lead to conformational instability and reduced functional activity of OR4C13. | ||||||
2,4-Dinitrophenol, wetted | 51-28-5 | sc-238345 | 250 mg | $58.00 | 2 | |
Dinitrophenol uncouples oxidative phosphorylation, impeding ATP synthesis. Insufficient ATP can cause a decrease in the conformational stability of OR4C13, which relies on ATP for proper function. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin inhibits PI3K, a kinase involved in signaling pathways that regulate protein synthesis and turnover. Inhibition of PI3K could reduce phosphorylation of proteins that interact with OR4C13, leading to its decreased functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, reducing AKT signaling and phosphorylation of downstream proteins. If OR4C13's activity is regulated by proteins modulated by PI3K/AKT signaling, its activity would decrease as well. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine broadly inhibits kinases, affecting phosphorylation of proteins in signaling networks. A decrease in phosphorylation events within OR4C13's network could reduce its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, causing downregulation of protein synthesis. This can decrease the production of proteins that regulate OR4C13, leading to a reduction in its functional activity. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C crosslinks DNA, inhibiting the cell cycle and reducing protein synthesis capacity. This could indirectly affect OR4C13's levels and function. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits CDKs, impeding cell cycle progression and potentially decreasing turnover of proteins that regulate OR4C13, leading to its functional inhibition. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin inhibits Hsp90, destabilizing client proteins. If OR4C13 relies on Hsp90 for folding or function, or if it interacts with Hsp90 client proteins, its activity would be decreased. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK, disrupting the MAPK pathway. If OR4C13's function is regulated by this pathway, its activity would be reduced following MEK inhibition. | ||||||